Replies to post #11225 on BioCurex, Inc.(fka BOCX)

[opportunityknocking]

In the Matritech deal they received 6 1/2 times their market cap (total 38 million dollars received for a less than 6 million dollar market cap company). That would give us about 4.50 a share.
However, the extreme difference is that they were a one trick pony....bladder cancer. We have so much more potential being that we have the only universal cancer marker. I'm not even sure how reliable that test is. It was already approved for point of care by the FDA when Inverness bought the company. We may be able to use their model and timeline to figure out where we stand in regards to Recaf point of care testing.
Just this morning, I received news of a client with breast cancer and will undergo double mastectomy. It breaks my heart that this could have been averted if Recaf was on the market. I didn't even want to bring this up to her, because it would only cause anger added to her grief.